Motilal Oswal is bullish on Piramal Pharma has recommended buy rating on the stock with a target price of Rs 310 in its research report dated October 24, 2024.
Pentair (NYSE:PNR – Free Report) had its price objective raised by JPMorgan Chase & Co. from $106.00 to $110.00 in a research report report published on Wednesday morning, Benzinga reports. The firm ...